The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
Open accessAbstract
Purpose: Since the clinical introduction of 68 Ga-PSMA-11 PET/CT, this imaging method has rapidly spread and is now regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). The aim of this study was to analyse the influence of several variables with possible influence on PSMA ligand uptake in a large cohort. Methods: We performed a retrospective analysis of 1007 consecutive patients who were scanned with 68 Ga-PSMA-11 PET/CT (1 h after injection) from January 2014 to January 2017 to detect recurrent disease. Patients with untreated primary PCa or patients referred for PSMA radioligand therapy were excluded. The possible effects of different variables including PSA level and PSA doubling time (PSA DT), PSA velocity (PSA Vel), Gleason score (GSC, including separate analysis of GSC 7a and 7b), ongoing androgen deprivation therapy (ADT), patient age and amount of injected activity were evaluated. Results: In 79.5% of patients at least one lesion with characteristics suggestive of recurrent PCa was detected. A pathological (positive) PET/CT scan was associated with PSA level and ADT. GSC, amount of injected activity, patient age, PSA DT and PSA Vel were not associated with a positive PET/CT scan in multivariate analysis. Conclusion: 68 Ga-PSMA-11 PET/CT detects tumour lesions in a high percentage of patients with recurrent PCa. Tumour detection is clearly associated with PSA level and ADT. Only a tendency for an association without statistical significance was found between higher GSC and a higher probability of a pathological PET/CT scan. No associations were found between a pathological 68 Ga-PSMA-11 PET/CT scan and patient age, amount of injected activity, PSA DT or PSA Vel.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
(1997) · PubMed · Cited by 1,541
Eiber, M., Maurer, T., Souvatzoglou, M., Beer, A. J., Ruffani, A., Haller, B., Graner, F.-P., Kübler, H., Haberhorn, U., Eisenhut, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.154153 · Cited by 994
Self-citationAfshar-Oromieh, A., Avtzi, E., Giesel, F. L., Holland-Letz, T., Linhart, H. G., Eder, M., Eisenhut, M., Boxler, S., Hadaschik, B. A., Kratochwil, C., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2949-6 · Cited by 964
Self-citationAfshar-Oromieh, A., Zechmann, C. M., Malcher, A., Eder, M., Eisenhut, M., Linhart, H. G., Holland-Letz, T., Hadaschik, B. A., Giesel, F. L., Debus, J., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2525-5 · Cited by 921
Self-citationAfshar-Oromieh, A., Malcher, A., Eder, M., Eisenhut, M., Linhart, H. G., Hadaschik, B. A., Holland-Letz, T., Giesel, F. L., Kratochwil, C., Haufe, S., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2298-2 · Cited by 915
Self-citationUpregulation of prostate-specific membrane antigen after androgen-deprivation therapy
Wright, G. L., Mayer Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., & Moriarty, R. (1996) · Urology · doi:10.1016/s0090-4295(96)00184-7 · Cited by 635
Sweat, S. D., Pacelli, A., Murphy, G. P., & Bostwick, D. G. (1998) · Urology · doi:10.1016/s0090-4295(98)00278-7 · Cited by 607
Expression of the prostate-specific membrane antigen.
Israeli, R., Powell, C. T., Corr, J., Fair, W. R., & Heston, W. D. W. (1994) · PubMed · Cited by 601
Morigi, J. J., Stricker, P. D., van Leeuwen, P. J., Tang, R., Ho, B., Nguyen, Q., Hruby, G., Fogarty, G., Jagavkar, R., Kneebone, A., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.160382 · Cited by 571
Ross, J. S., Sheehan, C. E., Fisher, H. A. �., Kaufman, R. P., Kaur, P., Gray, K., Webb, I. J., Gray, G. S., Mosher, R. E., & Kallakury, B. (2003) · PubMed · Cited by 513
Szabo, Z., Mena, E., Rowe, S. P., Plyku, D., Nidal, R., Eisenberger, M. A., Antonarakis, E. S., Fan, H., Dannals, R. F., Chen, Y., et al. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0850-8 · Cited by 443
Afshar-Oromieh, A., Hetzheim, H., Kratochwil, C., Benesova, M., Eder, M., Neels, O. C., Eisenhut, M., Kübler, W., Holland-Letz, T., Giesel, F. L., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.161299 · Cited by 427
Self-citationEder, M., Neels, O., Müller, M., Bauder-Wüst, U., Remde, Y., Schäfer, M., Hennrich, U., Eisenhut, M., Afshar-Oromieh, A., Haberkorn, U., et al. (2014) · Pharmaceuticals · doi:10.3390/ph7070779 · Cited by 370
Self-citationZechmann, C. M., Afshar-Oromieh, A., Armor, T., Stubbs, J. B., Mier, W., Hadaschik, B., Joyal, J., Kopka, K., Debus, J., Babich, J. W., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2713-y · Cited by 358
Self-citationEvans, M. J., Smith-Jones, P. M., Wongvipat, J., Navarro, V., Kim, S., Bander, N. H., Larson, S. M., & Sawyers, C. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106383108 · Cited by 316
THE RELATIVE IMPACT AND FUTURE BURDEN OF PROSTATE CANCER IN THE UNITED STATES
CHAN, J. M., JOU, R. M., & CARROLL, P. R. (2004) · Journal of Urology · doi:10.1097/01.ju.0000142068.66876.53 · Cited by 303
Herlemann, A., Wenter, V., Kretschmer, A., Thierfelder, K. M., Bartenstein, P., Faber, C., Gildehaus, F.-J., Stief, C. G., Gratzke, C., & Fendler, W. P. (2016) · European Urology · doi:10.1016/j.eururo.2015.12.051 · Cited by 295
Minner, S., Wittmer, C., Graefen, M., Salomon, G., Steuber, T., Haese, A., Huland, H., Bokemeyer, C., Yekebas, E., Dierlamm, J., et al. (2011) · The Prostate · doi:10.1002/pros.21241 · Cited by 284
Schwenck, J., Rempp, H., Reischl, G., Kruck, S., Stenzl, A., Nikolaou, K., Pfannenberg, C., & la Fougère, C. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3490-6 · Cited by 269
Ceci, F., Uprimny, C., Nilica, B., Geraldo, L., Kendler, D., Kroiss, A., Bektic, J., Horninger, W., Lukas, P., Decristoforo, C., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3078-6 · Cited by 262
Prostate-specific Membrane Antigen–radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer
Maurer, T., Weirich, G., Schottelius, M., Weineisen, M., Frisch, B., Okur, A., Kübler, H., Thalgott, M., Navab, N., Schwaiger, M., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.04.034 · Cited by 233
68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience
Hope, T. A., Truillet, C., Ehman, E. C., Afshar-Oromieh, A., Aggarwal, R., Ryan, C. J., Carroll, P. R., Small, E. J., & Evans, M. J. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.181800 · Cited by 214
Self-citation18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer
Rowe, S. P., Gage, K. L., Faraj, S. F., Macura, K. J., Cornish, T. C., Gonzalez-Roibon, N., Guner, G., Munari, E., Partin, A. W., Pavlovich, C. P., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.154336 · Cited by 196
Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing
Afshar-Oromieh, A., Hetzheim, H., Kübler, W., Kratochwil, C., Giesel, F. L., Hope, T. A., Eder, M., Eisenhut, M., Kopka, K., & Haberkorn, U. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3419-0 · Cited by 185
Self-citationVerburg, F. A., Pfister, D., Heidenreich, A., Vogg, A., Drude, N. I., Vöö, S., Mottaghy, F. M., & Behrendt, F. F. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3240-1 · Cited by 182
Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT
Rowe, S. P., Gorin, M. A., Hammers, H. J., Som Javadi, M., Hawasli, H., Szabo, Z., Cho, S. Y., Pomper, M. G., & Allaf, M. E. (2015) · Annals of Nuclear Medicine · doi:10.1007/s12149-015-1017-z · Cited by 172
Herrmann, K., Bluemel, C., Weineisen, M., Schottelius, M., Wester, H., Czernin, J. G., Eberlein, U., Beykan, S., Lapa, C., Riedmiller, H. N., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.156133 · Cited by 148
68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma
Demirci, E., Ocak, M., Kabasakal, L., Decristoforo, C., Talat, Z., Halaç, M., & Kanmaz, B. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2766-y · Cited by 140
Rhee, H., Blazak, J., Tham, C. M., Ng, K. L., Shepherd, B., Lawson, M., Preston, J. M., Vela, I., Thomas, P. A., & Wood, S. (2016) · EJNMMI Research · doi:10.1186/s13550-016-0231-6 · Cited by 138
Afshar‐Oromieh, A., Sattler, L. P., Mier, W., Hadaschik, B. A., Debus, J., Holland‐Letz, T., Kopka, K., & Haberkorn, U. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183483 · Cited by 133
Self-citationFirst evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CT
Verburg, F. A., Krohn, T., Heinzel, A., Mottaghy, F. M., & Behrendt, F. F. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3065-y · Cited by 132
Hijazi, S., Meller, B., Leitsmann, C., Strauß, A., Meller, J., Ritter, C. O., Lotz, J., Schildhaus, H., Trojan, L., & Sahlmann, C. O. (2015) · The Prostate · doi:10.1002/pros.23091 · Cited by 130
Marchal, C., Redondo, M., Padilla, M., Caballero, J., Rodrigo, I., Garcia, J., Quian, J., & Boswick, D. G. (2004) · PubMed · doi:10.14670/hh-19.715 · Cited by 129
Kasperzyk, J. L., Finn, S. P., Flavin, R., Fiorentino, M., Lis, R. L., Hendrickson, W. K., Clinton, S. K., Sesso, H. D., Giovannucci, E. L., Stampfer, M. J., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0668 · Cited by 127
68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
Sathekge, M. M., Lengana, T., Modiselle, M., Vorster, M., Zeevart, J., Maes, A., Ebenhan, T., & de Wiele, C. V. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3563-6 · Cited by 120
68Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma
Sasikumar, A., Joy, A., Nanabala, R., Pillai, M. R. A., Thomas, B., & Vikraman, K. R. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3297-x · Cited by 113
Sawicki, L. M., Buchbender, C., Boos, J., Giessing, M., Ermert, J., Antke, C., Antoch, G., & Hautzel, H. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3360-2 · Cited by 104
Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT
Artigas, C., Alexiou, J., Garcia, C. A., Wimana, Z., Otte, F.-X., Gil, T., Velthoven, R. V., & Flamen, P. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3236-x · Cited by 98
Pfob, C. H., Ziegler, S. I., Graner, F. P., Köhner, M., Schachoff, S., Blechert, B., Wester, H., Scheidhauer, K., Schwaiger, M., Maurer, T., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3424-3 · Cited by 87
Biphasic 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma
Sahlmann, C., Meller, B., Bouter, C., Ritter, C. O., Ströbel, P., Lotz, J., Trojan, L., Meller, J., & Hijazi, S. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3251-y · Cited by 82
Rischpler, C., Maurer, T., Schwaiger, M., & Eiber, M. J. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3235-y · Cited by 69
Liu, T., Wu, L. Y., Fulton, M. D., JOHNSON, J. M., & Berkman, C. E. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1649 · Cited by 63
Subacute Stroke Mimicking Cerebral Metastasis in 68Ga-PSMA-HBED-CC PET/CT
Noto, B., Vrachimis, A., Schäfers, M. A., Stegger, L., & Rahbar, K. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001291 · Cited by 62
68Ga-PSMA PET/CT False-Positive Tracer Uptake in Paget Disease
Sasikumar, A., Joy, A., Nanabala, R., Pillai, M. R. A., & Hari, T. A. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001340 · Cited by 59
Rowe, S. P., Gorin, M. A., Hammers, H. J., Pomper, M. G., Allaf, M. E., & Javadi, M. S. (2015) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000995 · Cited by 57
Prostate-Specific Membrane Antigen PET/CT Findings for Hepatic Hemangioma
Bhardwaj, H., Stephens, M., Bhatt, M. K., & Thomas, P. A. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001384 · Cited by 51
Bilgin, R., Ergül, N., & Çermik, T. F. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001406 · Cited by 45
Prostate-Specific Membrane Antigen PET/CT: Uptake in Lymph Nodes With Active Sarcoidosis
Dias, A. H., Vendelbo, M. H., & Bouchelouche, K. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001528 · Cited by 37
Schwannoma Showing Avid Uptake on 68Ga-PSMA-HBED-CC PET/CT
Kanthan, G. L., Izard, M. A., Emmett, L., Hsiao, E., & Schembri, G. P. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001281 · Cited by 36
Zacho, H. D., Nielsen, J. B., Dettmann, K., Haberkorn, U., & Petersen, L. J. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001522 · Cited by 35
Self-citationSubcutaneous Lobular Capillary Hemangioma on 68Ga-PSMA PET/CT
Jochumsen, M. R., Vendelbo, M. H., Høyer, S., & Bouchelouche, K. (2017) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001542 · Cited by 29
Cited by
Hofman, M. S., Lawrentschuk, N., Francis, R. J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J. M., Frydenberg, M., Shakher, R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30314-7 · Cited by 2,040
Perera, M., Papa, N., Roberts, M., Williams, M., Udovicich, C., Vela, I., Christidis, D., Bolton, D., Hofman, M. S., Lawrentschuk, N., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.01.049 · Cited by 958
Fendler, W. P., Calais, J., Eiber, M., Flavell, R. R., Mishoe, A., Feng, F. Y., Nguyen, H. G., Reiter, R. E., Rettig, M. B., Okamoto, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0096 · Cited by 779
Eiber, M., Herrmann, K., Calais, J., Hadaschik, B., Giesel, F. L., Hartenbach, M., Hope, T., Reiter, R., Maurer, T., Weber, W. A., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.198119 · Cited by 626
Self-citationCalais, J., Ceci, F., Eiber, M., Hope, T. A., Hofman, M. S., Rischpler, C., Bach-Gansmo, T., Nanni, C., Savir-Baruch, B., Elashoff, D., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30415-2 · Cited by 476
Metadata
- Authors
- Afshar-Oromieh, A., Holland-Letz, T., Giesel, F. L., Kratochwil, C., Mier, W., Haufe, S., Debus, N., Eder, M., Eisenhut, M., Schäfer, M., Neels, O., Hohenfellner, M., Kopka, K., Kauczor, H.-U., Debus, J., & Haberkorn, U.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2017-05-12
- Volume
- 44
- Issue
- 8
- Pages
- 1258-1268
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2612014481
- Cited by
- 507
- References
- 52
- FWCI
- 58.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.